Diligence memo · auto-generated · as of July 2, 2026
QUATRX PHARMACEUTICALS Co
QUATRX PHARMACEUTICALS Co looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
QUATRX PHARMACEUTICALS Co operates in Pharmaceuticals, based in ANN ARBOR.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
QUATRX PHARMACEUTICALS Co has raised $14M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $14M on 2009-03-30.
Most recent recorded round closed around 2009-03-30.
Valuation (modeled)modeled
Provath models QUATRX PHARMACEUTICALS Co at approximately $434M (range $16M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.58× the median modeled value of Series A Pharmaceuticals companies in 2007–2009 (18 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 17.3 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 60% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 79% of those peers.
Closest niche peers: Sinocom Pharmaceutical, Inc., Vitae Pharmaceuticals, Inc, Qrxpharma Ltd, Elixir Pharmaceuticals, Inc., Bayhill Therapeutics, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.